Prognostic impact of myocardial interstitial fibrosis in non-ischemic heart failure: Comparison between preserved and reduced ejection fraction heart failure

Circulation Journal

Volumn 75, Issue 11, 2011, Pages 2605-2613

  Aoki, Tatsuo ^a   Fukumoto, Yoshihiro ^a   Sugimura, Koichiro ^a   Oikawa, Minako ^a   Satoh, Kimio ^a   Nakano, Makoto ^a   Nakayama, Masaharu ^a   Shimokawa, Hiroaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Collagen volume fraction; Ejection fraction; Fibrosis; Heart failure; Prognosis

Indexed keywords

ADULT; ARTICLE; COLLAGEN VOLUME FRACTION; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; MYOCARDIAL INTERSTITIAL FIBROSIS; PREDICTIVE VALUE; PROGNOSIS; SURVIVAL TIME;

ADULT; AGED; BIOPSY; BLOOD PRESSURE; ENDOMYOCARDIAL FIBROSIS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STROKE VOLUME; SURVIVAL RATE;

EID: 80054948842     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0568     Document Type: Article

References (45)

1. Janicki J, Brower G. The role of myocardial fibrillar collagen in ventricular remodeling and function. J Card Fail 2002; 8(Suppl): S319-S325.
2. Fukumoto Y, Deguchi J, Libby P, Rabkin-Aikawa E, Sakata Y, Chin M, et al. Genetically determined resistance to collagenase action augments interstitial collagen accumulation in atherosclerotic plaques. Circulation 2004; 110: 1953-1959.
3. Borbély A, van der Velden J, Papp Z, Bronzwaer J, Edes I, Stienen G, et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation 2005; 111: 774-781.
4. Díez J, Querejeta R, López B, González A, Larman M, Martínez Ubago J. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002; 105: 2512-2517.
5. van Heerebeek L, Hamdani N, Handoko M, Falcao-Pires I, Musters R, Kupreishvili K, et al. Diastolic stiffness of the failing diabetic heart: Importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 2008; 117: 43-51.
6. Hein S, Arnon E, Kostin S, Schönburg M, Elsässer A, Polyakova V, et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: Structural deterioration and compensatory mechanisms. Circulation 2003; 107: 984-991.
7. Graham H, Trafford A. Spatial disruption and enhanced degradation of collagen with the transition from compensated ventricular hypertrophy to symptomatic congestive heart failure. Am J Physiol Heart 2007; 292: H1364-H1372.
8. Bello D, Fieno D, Kim R, Pereles F, Passman R, Song G, et al. Infarct morphology identifies patients with substrate for sustained ventricular tachycardia. J Am Coll Cardiol 2005; 45: 1104-1108.
9. Assomull R, Prasad S, Lyne J, Smith G, Burman E, Khan M, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006; 48: 1977-1985.
10. Jellis C, Martin J, Narula J, Marwick T. Assessment of nonischemic myocardial fibrosis. J Am Coll Cardiol 2010; 56: 89-97.
11. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the Randomized Aldactone Evaluation Study (RALES): RALES Investigators. Circulation 2000; 102: 2700-2706.
12. Cicoira M, Rossi A, Bonapace S, Zanolla L, Golia G, Franceschini L, et al. Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J Card Fail 2004; 10: 403-411.
13. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358: 2148-2159.
14. Soylemezoglu O, Wild G, Dalley AJ, MacNeil S, Milford-Ward A, Brown CB, et al. Urinary and serum type III collagen: Markers of renal fibrosis. Nephrol Dial Transplant 1997; 12: 1883-1889.
15. Leroy V. Other non-invasive markers of liver fibrosis. Gastroenterol Clin Biol 2008; 32(Suppl 1): 52-57.
16. van Heerebeek L, Borbély A, Niessen H, Bronzwaer J, van der Velden J, Stienen G, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006; 113: 1966-1973.
17. Fukui S, Fukumoto Y, Suzuki J, Saji K, Nawata J, Tawara S, et al. Long-term inhibition of Rho-kinase ameliorates diastolic heart failure in hypertensive rats. J Cardiovasc Pharmacol 2008; 51: 317-326.
18. Tribouilloy C, Rusinaru D, Mahjoub H, Soulière V, Lévy F, Peltier M, et al. Prognosis of heart failure with preserved ejection fraction: A 5 year prospective population-based study. Eur Heart J 2008; 29: 339-347.
19. Senni M, Redfield M. Heart failure with preserved systolic function: A different natural history? J Am Coll Cardiol 2001; 38: 1277-1282.
20. Miyagishima K, Hiramitsu S, Kimura H, Mori K, Ueda T, Kato S, et al. Long term prognosis of chronic heart failure: Reduced vs preserved left ventricular ejection fraction. Circ J 2009; 73: 92-99.
21. Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, Yokota T, Goto D, Yokoshiki H, et al. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction: Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 1893-1900.
22. Owan T, Hodge D, Herges R, Jacobsen S, Roger V, Redfield M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-259.
23. Capomolla S, Febo O, Ceresa M, Caporotondi A, Guazzotti G, La Rovere M, et al. Cost/utility ratio in chronic heart failure: Comparison between heart failure management program delivered by dayhospital and usual care. J Am Coll Cardiol 2002; 40: 1259-1266.
24. López B, González A, Querejeta R, Larman M, Díez J. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol 2006; 48: 89-96.
25. Schwartzkopff B, Fassbach M, Pelzer B, Brehm M, Strauer B. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail 2002; 4: 439-444.
26. Timonen P, Magga J, Risteli J, Punnonen K, Vanninen E, Turpeinen A, et al. Cytokines, interstitial collagen and ventricular remodelling in dilated cardiomyopathy. Int J Cardiol 2008; 124: 293-300.
27. Marijianowski M, Teeling P, Mann J, Becker A. Dilated cardiomyopathy is associated with an increase in the type I/type III collagen ratio: A quantitative assessment. J Am Coll Cardiol 1995; 25: 1263-1272.
28. Bello D, Shah D, Farah G, Di Luzio S, Parker M, Johnson M, et al. Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. Circulation 2003; 108: 1945-1953.
29. Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol 2008; 52: 1574-1580.
30. Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukena C, Athanasiadis A, et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: Differences in complication rate and diagnostic performance. Circulation 2010; 122: 900-909.
31. Bruch C, Gotzmann M, Stypmann J, Wenzelburger F, Rothenburger M, Grude M, et al. Electrocardiography and Doppler echocardiography for risk stratification in patients with chronic heart failure: Incremental prognostic value of QRS duration and a restrictive mitral filling pattern. J Am Coll Cardiol 2005; 45: 1072-1075.
32. Whalley G, Doughty R, Gamble G, Wright S, Walsh H, Muncaster S, et al. Pseudonormal mitral filling pattern predicts hospital re-admission in patients with congestive heart failure. J Am Coll Cardiol 2002; 39: 1787-1795.
33. Pitt B, Zannad F, Remme W, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
34. Izawa H, Murohara T, Nagata K, Isobe S, Asano H, Amano T, et al. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: A pilot study. Circulation 2005; 112: 2940-2945.
35. Brilla C, Funck R, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102: 1388-1393.
36. Brilla C, Rupp H, Maisch B. Effects of ACE inhibition versus non-ACE inhibitor antihypertensive treatment on myocardial fibrosis in patients with arterial hypertension: Retrospective analysis of 120 patients with left ventricular endomyocardial biopsies. Herz 2003; 28: 744-753.
37. Zile M, Gaasch W, Anand I, Haass M, Little W, Miller A, et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation 2010; 121: 1393-1405.
38. Yusuf S, Pfeffer M, Swedberg K, Granger C, Held P, McMurray J, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003; 362: 777-781.
39. Kitzman D, Hundley W, Brubaker P, Morgan T, Moore J, Stewart K, et al. A randomized, double-blinded trial of enalapril in older patients with heart failure and preserved ejection fraction: Effects on exercise tolerance and arterial distensibility. Circ Heart Fail 2010; 3: 477-485.
40. Parthasarathy H, Pieske B, Weisskopf M, Andrews C, Brunel P, Struthers A, et al. A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. Eur J Heart Fail 2009; 11: 980-989.
41. Cahill J, Ryan E, Travers B, Ryder M, Ledwidge M, McDonald K. Progression of preserved systolic function heart failure to systolic dysfunction: A natural history study. Int J Cardiol 2006; 106: 95-102.
42. Kass D, Bronzwaer J, Paulus W. What mechanisms underlie diastolic dysfunction in heart failure? Circ Res 2004; 94: 1533-1542.
43. Badenhorst D, Maseko M, Tsotetsi O, Naidoo A, Brooksbank R, Norton G, et al. Cross-linking influences the impact of quantitative changes in myocardial collagen on cardiac stiffness and remodelling in hypertension in rats. Cardiovasc Res 2003; 57: 632-641.
44. Woodiwiss A, Tsotetsi O, Sprott S, Lancaster E, Mela T, Chung E, et al. Reduction in myocardial collagen cross-linking parallels left ventricular dilatation in rat models of systolic chamber dysfunction. Circulation 2001; 103: 155-160.
45. López B, González A, Varo N, Laviades C, Querejeta R, Díez J. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 2001; 38: 1222-1226.